Introduction: All anticancer drugs can cause idiosyncratic liver injury. Therefore,
hepatoprotective agents assume particular importance to preserve liver function. Hepatic …

The liver has a key role in the metabolism (ie, inactivation or activation) of many commonly
used anticancer agents—cytotoxics or new biological agents. Therefore, assessment of liver …

BACKGROUND: The FDA has recently proposed pre-marketing liver chemistry subject
stopping criteria. The study was undertaken to determine the background rates of liver …

Introduction Despite being commonly recommended, the impact of anticancer drugs (ACDs)
on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) …

INTRODUCTION: Although existing evidence from clinical trials has demonstrated
manifestation of hepatic adverse events (AEs) with the use of tyrosine kinase inhibitors …

The drug‐induced liver injury (DILI)‐sim Initiative is a public‐private partnership involving
scientists from industry, academia, and the US Food and Drug Administration (FDA). The …

Purpose: The purpose of this study was to identify patient characteristics that may be risk
factors or markers of susceptibility to adverse treatment effects in cancer Phase I and II …

Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of
medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible …

Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

Introduction Phase I oncology trials have evolved over the years, and these changes could
have implications for future studies and patients. Methods Adult trials sponsored by Cancer …